Clinical breast cancer · 2026
Lymph Node Ratio as an Independent Prognostic Factor in Breast Cancer: A Retrospective Study of 4060 Patients Undergoing Axillary Lymph Node Dissection.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mishra Ashutosh, Deo Svs, Bagla Chinmay, Bhoriwal Sandeep, Sharma Jyoti, Kumar Naveen, Saikia Jyoutishman, Bansal Babul, Kumar Sunil, Gogia Ajay, Batra Atul, Sharma D N, Mathur Sandeep
Аннотация
BACKGROUND: Pathological nodal (pN) staging in breast cancer is based on the number of positive nodes but may be influenced by surgical extent and technique. Lymph node ratio (LNR)-the ratio of positive to total nodes-accounts for both tumor burden and nodal yield, potentially improving prognostic accuracy.
METHODS: We retrospectively analyzed data from 4060 breast cancer patients who underwent axillary lymph node dissection (ALND) between 1995 and 2021 at a tertiary cancer center in India. Disease-free survival (DFS) and overall survival (OS) were assessed using Kaplan-Meier curves and log-rank tests. Correlation analysis and multivariate analysis were used to compare prognostic utility of LNR versus pN stage. Optimal LNR cutoffs were identified using Youden's index.
RESULTS: The median follow-up was 93.8 months. On multivariate analysis, LNR retained a strong independent prognostic value for both DFS (HR = 2.00 for LNR 0.2-0.5; HR = 3.29 for LNR > 0.5; P < .001) and OS (HR = 1.77 for LNR 0.2 to 0.5; HR = 2.77 for LNR > 0.5; P < .001). LNR cutoffs of 0.24 (DFS) and 0.21 (OS) were identified. Stratification into 3 LNR groups (≤ 0.20, 0.21-0.50, > 0.50) showed significantly different survival outcomes (log-rank P < 0.001).
CONCLUSIONS: LNR is a superior and independent prognostic marker compared to pN stage in breast cancer patients undergoing ALND. Incorporating LNR into prognostic models may enhance risk stratification and guide adjuvant treatment decisions.
METHODS: We retrospectively analyzed data from 4060 breast cancer patients who underwent axillary lymph node dissection (ALND) between 1995 and 2021 at a tertiary cancer center in India. Disease-free survival (DFS) and overall survival (OS) were assessed using Kaplan-Meier curves and log-rank tests. Correlation analysis and multivariate analysis were used to compare prognostic utility of LNR versus pN stage. Optimal LNR cutoffs were identified using Youden's index.
RESULTS: The median follow-up was 93.8 months. On multivariate analysis, LNR retained a strong independent prognostic value for both DFS (HR = 2.00 for LNR 0.2-0.5; HR = 3.29 for LNR > 0.5; P < .001) and OS (HR = 1.77 for LNR 0.2 to 0.5; HR = 2.77 for LNR > 0.5; P < .001). LNR cutoffs of 0.24 (DFS) and 0.21 (OS) were identified. Stratification into 3 LNR groups (≤ 0.20, 0.21-0.50, > 0.50) showed significantly different survival outcomes (log-rank P < 0.001).
CONCLUSIONS: LNR is a superior and independent prognostic marker compared to pN stage in breast cancer patients undergoing ALND. Incorporating LNR into prognostic models may enhance risk stratification and guide adjuvant treatment decisions.